ADHD Drug Compositions with Delayed Release Layers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ADHD and other CNS stimulant-responsive conditions face challenges in maintaining effective drug concentration throughout the day, particularly in morning and afternoon when cognitive abilities are needed, due to the need for multiple daily doses and variability in patient sleep schedules.
Innovation Solution
Development of novel pharmaceutical compositions with a core comprising a CNS stimulant, a sustained release layer, and a delayed release layer, allowing for a single evening dose that provides a controlled release of the drug over 4 to 12 hours, ensuring therapeutic levels at wake-up and throughout the day, with adjustable lag times and pH-dependent release mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple daily doses of immediate release formulation are administered, then effective drug concentration can be maintained throughout the day, but patient compliance deteriorates due to frequent administration
Solution Approach 1:
The formulation is segmented into multiple functional layers: an immediate release layer for rapid therapeutic effect, a sustained release layer for extended drug delivery, and a delayed release outer layer for pH-dependent release control. This segmentation allows the single dose to provide therapeutic coverage throughout the day, eliminating the need for multiple administrations while maintaining effective drug concentrations.
Solution Approach 2:
The delayed release outer layer is designed to prevent drug release during the initial gastric transit period, allowing the formulation to be taken in the evening before bed. The drug is preliminarily contained and released only after the formulation reaches the appropriate pH environment in the intestine, ensuring therapeutic levels are achieved at the appropriate time without requiring multiple doses.
2Ease of operation
If long-acting formulations with 8-14 hour duration are used, then patient compliance improves with single daily administration, but effective coverage in morning and afternoon deteriorates due to insufficient duration
Solution Approach 1:
The formulation provides continuous drug release through multiple overlapping mechanisms: immediate release from the inner layer, sustained release from the middle layer, and delayed release from the outer layer. This continuous action ensures therapeutic drug levels are maintained from evening administration through morning wake-up and throughout the active daytime hours, providing uninterrupted therapeutic coverage.
Solution Approach 2:
The formulation utilizes pH as a changing parameter to control drug release timing. The delayed release outer layer remains intact in the acidic gastric environment (pH 1-3) and dissolves at the higher pH of the intestine (pH 6-7.5), allowing the drug to be released at the appropriate time to cover morning and afternoon therapeutic needs while maintaining single-dose convenience.
3Speed
If drug release begins immediately after administration, then rapid therapeutic effect is achieved, but side effects increase during sleep hours when drug is not needed
Solution Approach 1:
The delayed release outer layer acts as an intermediary barrier that prevents drug release during gastric transit and sleep hours. This protective layer dissolves only when the formulation reaches the intestinal environment with appropriate pH, allowing rapid therapeutic effect to begin at the correct time while preventing harmful side effects during periods when the drug is not therapeutically needed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions provide a convenient, sustained therapeutic effect from wake-up to the active part of the day with reduced side effects, improving ADHD-related behavior and cognitive abilities for 12 to 24 hours, as measured by validated rating scales, and can be adapted for various sleep patterns.
Implementation Method 1
The outer layer is a delayed release layer that is insoluble in an aqueous medium at a pH below 5.5... The unit dose provides a lag period of at least 5 hours during which the plasma concentration of methylphenidate is less than 10% of the maximum concentration
Implementation Method 2
a sustained release layer enclosing the core... providing a controlled release of the drug over 4 to 12 hours
Data Source
AI summary
Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.